Human Phenotypes and Animal Knockout Models of Genetic Autonomic Disorders

Norepinephrine (NE) is a crucial neurotransmitter involved in autonomic regulation of blood pressure. Dopamine β-hydroxylase (DBH), the norepinephrine transporter (NET), and the vesicular monoamine transporter subtype 2 catalyze intracellular NE biosynthesis, NE reuptake from the synapse, and vesicular transport, respectively. Genetic disorders in humans have been identified that render DBH, and the NET dysfunctional and result in cardiovascular and neurological abnormalities. Vesicular monoamine transporter subtype 2 (VMAT2) activity protects against neurotoxins, and reduced VMAT2 expression is implicated in drug addiction. Further investigation of the consequences of these genetic abnormalities has been achieved by the construction of mice strains deficient in the genes encoding DBH, NET, and VMAT2.

[1]  R. Palmiter,et al.  Noradrenaline is essential for mouse fetal development , 1995, Nature.

[2]  R. Edwards,et al.  The role of vesicular transport proteins in synaptic transmission and neural degeneration. , 1997, Annual review of neuroscience.

[3]  D. Robertson,et al.  The broader view: catecholamine abnormalities , 2002, Clinical Autonomic Research.

[4]  I. Sora,et al.  Heterozygous VMAT2 knockout mice display prolonged QT intervals: possible contributions to sudden death. , 1999, Brain research. Molecular brain research.

[5]  Arya M. Sharma,et al.  Selective Norepinephrine Reuptake Inhibition as a Human Model of Orthostatic Intolerance , 2002, Circulation.

[6]  F. Bymaster,et al.  Clinical Assessment of Norepinephrine Transporter Blockade Through Biochemical and Pharmacological Profiles , 2004, Circulation.

[7]  Steven A. Thomas,et al.  Thermoregulatory and metabolic phenotypes of mice lacking noradrenaline and adrenaline , 1997, nature.

[8]  R. Blakely,et al.  A Mutation in the Human Norepinephrine Transporter Gene (SLC6A2) Associated with Orthostatic Intolerance Disrupts Surface Expression of Mutant and Wild-Type Transporters , 2003, The Journal of Neuroscience.

[9]  R. Gainetdinov,et al.  Plasma membrane monoamine transporters: structure, regulation and function , 2003, Nature Reviews Neuroscience.

[10]  J. Phillips,et al.  Dopamine /8‐Hydroxylase Deficiency A Genetic Disorder of Cardiovascular Regulation , 1991, Hypertension.

[11]  D. O'Connor,et al.  Vesicular monoamine transport inhibitors. Novel action at calcium channels to prevent catecholamine secretion. , 1996, Hypertension.

[12]  Robert P. Carson,et al.  Animal Model of Neuropathic Tachycardia Syndrome , 2001, Hypertension.

[13]  R. Blakely,et al.  Familial Orthostatic Tachycardia Due to Norepinephrine Transporter Deficiency , 2001, Annals of the New York Academy of Sciences.

[14]  K Kramer,et al.  A new method for measurement of blood pressure, heart rate, and activity in the mouse by radiotelemetry. , 2000, Journal of applied physiology.

[15]  P. Bruneval,et al.  Fluospheres for cardiovascular phenotyping genetically modified mice. , 2000, Journal of cardiovascular pharmacology.

[16]  R. Blakely,et al.  A Regulated Interaction of Syntaxin 1A with the Antidepressant-Sensitive Norepinephrine Transporter Establishes Catecholamine Clearance Capacity , 2003, The Journal of Neuroscience.

[17]  J. Axelrod,et al.  Dopamine- -hydroxylase: regulation of its synthesis and release from nerve terminals. , 1972, Pharmacological reviews.

[18]  J. Montani,et al.  Direct and indirect methods used to study arterial blood pressure. , 2000, Journal of pharmacological and toxicological methods.

[19]  R. Blakely,et al.  Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. , 2000, The New England journal of medicine.

[20]  R. Palmiter,et al.  Enhanced contractility and decreased beta-adrenergic receptor kinase-1 in mice lacking endogenous norepinephrine and epinephrine. , 1999, Circulation.

[21]  R. Blakely,et al.  Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders , 2002, The Pharmacogenomics Journal.

[22]  G. Jacob,et al.  Idiopathic orthostatic intolerance and postural tachycardia syndromes. , 1999, The American journal of the medical sciences.

[23]  F. Boomsma,et al.  CONGENITAL DOPAMINE-BETA-HYDROXYLASE DEFICIENCY A Novel Orthostatic Syndrome , 1987, The Lancet.

[24]  Robert P. Carson,et al.  Genetic manipulation of noradrenergic neurons. , 2002, The Journal of pharmacology and experimental therapeutics.

[25]  G. Eisenhofer,et al.  Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anaesthetized dog , 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

[26]  I. Sora,et al.  The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  Kwang-Soo Kim,et al.  A Proximal Promoter Domain Containing a Homeodomain-Binding Core Motif Interacts with Multiple Transcription Factors, Including HoxA5 and Phox2 Proteins, and Critically Regulates Cell Type-Specific Transcription of the Human Norepinephrine Transporter Gene , 2002, The Journal of Neuroscience.

[28]  Avid,et al.  ORTHOSTATIC INTOLERANCE AND TACHYCARDIA ASSOCIATED WITH NOREPINEPHRINE-TRANSPORTER DEFICIENCY ORTHOSTATIC INTOLERANCE AND TACHYCARDIA ASSOCIATED WITH NOREPINEPHRINE-TRANSPORTER DEFICIENCY , 2000 .

[29]  Italo Biaggioni,et al.  Dopamine β-Hydroxylase Immunoreactivity in Human Cerebrospinal Fluid: Properties, Relationship to Central Noradrenergic Neuronal Activity and Variation in Parkinson's Disease and Congenital Dopamine β-Hydroxylase Deficiency , 1994 .

[30]  Graeme Eisenhofer,et al.  Sources and Significance of Plasma Levels of Catechols and Their Metabolites in Humans , 2003, Journal of Pharmacology and Experimental Therapeutics.

[31]  B. Cohen,et al.  Mutations in the dopamine beta-hydroxylase gene are associated with human norepinephrine deficiency. , 2002, American journal of medical genetics.

[32]  J. Onrot,et al.  Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired beta-hydroxylation of dopamine. , 1986, The New England journal of medicine.